Related Experiment Video
Updated: Dec 24, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Nintedanib-induced glomerular microangiopathy: a case report
Masataka Hasegawa1, Atsuko Uehara2, Tomo Suzuki1,3
1Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.
Abstract:
Nintedanib, a triple tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has been used in idiopathic pulmonary fibrosis and adenocarcinoma in advanced non-small cell lung cancer. Although vascular endothelial growth factor inhibitors have been reported to cause endothelial injury and glomerular microangiopathy, nintedanib-induced glomerular microangiopathy has not been reported. A 68-year-old man with a history of primary aldosteronism, idiopathic pulmonary fibrosis, and pleomorphic carcinoma of the lung developed proteinuria and leg edema after nintedanib initiation. Kidney biopsy revealed prominent endothelial and mesangial injury. Proteinuria improved after nintedanib withdrawal. To the best of our knowledge, this is the second case report of nintedanib-induced glomerular microangiopathy. Although the incidence of nephropathy among patients receiving nintedanib is unknown at this moment, we recommend monitoring urinary protein excretion and blood pressure in patients receiving nintedanib and performing kidney biopsy to determine any histopathological change.
Insights
Nintedanib, a tyrosine kinase inhibitor, may cause glomerular microangiopathy, a rare kidney injury. Monitoring kidney function is recommended for patients on this medication.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Nintedanib is a triple tyrosine kinase inhibitor used for idiopathic pulmonary fibrosis and advanced non-small cell lung cancer.
- Vascular endothelial growth factor inhibitors are known to cause endothelial injury and glomerular microangiopathy.
Observation:
- A 68-year-old male patient developed proteinuria and leg edema after initiating nintedanib.
- Kidney biopsy showed significant endothelial and mesangial injury.
Findings:
- This case represents the second report of nintedanib-induced glomerular microangiopathy.
- Proteinuria resolved upon discontinuation of nintedanib, suggesting a causal link.
Implications:
- Nintedanib may induce glomerular microangiopathy, necessitating vigilance in patients undergoing treatment.
- Monitoring urinary protein excretion and blood pressure is crucial for early detection of nintedanib-induced nephropathy.
- Kidney biopsy is essential for diagnosing nintedanib-induced glomerular microangiopathy and guiding management.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
Related Concept Videos
Nephrotic Syndrome I : Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury III: Clinical Manifestations